<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Blood</journal-id>
        <journal-id journal-id-type="iso-abbrev">Blood</journal-id>
        <journal-id journal-id-type="pmc-domain-id">446</journal-id>
        <journal-id journal-id-type="pmc-domain">blood</journal-id>
        <journal-id journal-id-type="publisher-id">Blood</journal-id>
        <journal-title-group>
          <journal-title>Blood</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0006-4971</issn>
        <issn pub-type="epub">1528-0020</issn>
        <publisher>
          <publisher-name>The American Society of Hematology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8057264</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8057264.1</article-id>
        <article-id pub-id-type="pmcaid">8057264</article-id>
        <article-id pub-id-type="pmcaiid">8057264</article-id>
        <article-id pub-id-type="pmid">33067607</article-id>
        <article-id pub-id-type="doi">10.1182/blood.2020008017</article-id>
        <article-id pub-id-type="publisher-id">2020/BLD2020008017</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="hwp-journal-coll">
            <subject>39</subject>
          </subj-group>
          <subj-group subj-group-type="heading">
            <subject>Lymphoid Neoplasia</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5190-6353</contrib-id>
            <name name-style="western">
              <surname>Bala Tannan</surname>
              <given-names initials="N">Neeta</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1163-9649</contrib-id>
            <name name-style="western">
              <surname>Manzari</surname>
              <given-names initials="MT">Mandana T.</given-names>
            </name>
            <xref ref-type="aff" rid="aff2">2</xref>
            <xref ref-type="author-notes" rid="fn1">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8607-8380</contrib-id>
            <name name-style="western">
              <surname>Herviou</surname>
              <given-names initials="L">Laurie</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
            <xref ref-type="author-notes" rid="fn1">
              <sup>*</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Da Silva Ferreira</surname>
              <given-names initials="M">Mariana</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hagen</surname>
              <given-names initials="C">Connor</given-names>
            </name>
            <xref ref-type="aff" rid="aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0180-8813</contrib-id>
            <name name-style="western">
              <surname>Kiguchi</surname>
              <given-names initials="H">Hiroto</given-names>
            </name>
            <xref ref-type="aff" rid="aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0915-6696</contrib-id>
            <name name-style="western">
              <surname>Manova-Todorova</surname>
              <given-names initials="K">Katia</given-names>
            </name>
            <xref ref-type="aff" rid="aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Seshan</surname>
              <given-names initials="V">Venkatraman</given-names>
            </name>
            <xref ref-type="aff" rid="aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>de Stanchina</surname>
              <given-names initials="E">Elisa</given-names>
            </name>
            <xref ref-type="aff" rid="aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6866-0000</contrib-id>
            <name name-style="western">
              <surname>Heller</surname>
              <given-names initials="DA">Daniel A.</given-names>
            </name>
            <xref ref-type="aff" rid="aff2">2</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <name name-style="western">
              <surname>Younes</surname>
              <given-names initials="A">Anas</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
            <xref ref-type="aff" rid="aff6">6</xref>
          </contrib>
          <aff id="aff1"><label>1</label>Department of Medicine, </aff>
          <aff id="aff2"><label>2</label>Molecular Pharmacology Program, </aff>
          <aff id="aff3"><label>3</label>Antitumor Assessment Core, </aff>
          <aff id="aff4"><label>4</label>Molecular Cytogenetics Core, </aff>
          <aff id="aff5"><label>5</label>Department of Epidemiology and Biostatistics, and </aff>
          <aff id="aff6"><label>6</label>Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        </contrib-group>
        <author-notes>
          <fn fn-type="equal" id="fn1">
            <label>*</label>
            <p>M.T.M. and L.H. contributed equally to this study.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>15</day>
          <month>4</month>
          <year>2021</year>
        </pub-date>
        <pub-date pub-type="epreprint">
          <day>16</day>
          <month>10</month>
          <year>2020</year>
        </pub-date>
        <volume>137</volume>
        <issue>15</issue>
        <issue-id pub-id-type="pmc-issue-id">380041</issue-id>
        <fpage>2057</fpage>
        <lpage>2069</lpage>
        <history>
          <date date-type="received">
            <day>09</day>
            <month>7</month>
            <year>2020</year>
          </date>
          <date date-type="accepted">
            <day>17</day>
            <month>9</month>
            <year>2020</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>15</day>
              <month>04</month>
              <year>2022</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>15</day>
              <month>04</month>
              <year>2022</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2022-04-15 00:16:43.790">
              <day>15</day>
              <month>04</month>
              <year>2022</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>Â© 2021 by The American Society of Hematology</copyright-statement>
          <copyright-year>2021</copyright-year>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bloodBLD2020008017.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="bloodBLD2020008017.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="icon" xlink:href="bloodBLD2020008017_thumb.jpg"/>
        <abstract abstract-type="executive-summary">
          <title>Key Points</title>
          <p>
            <list list-type="bullet">
              <list-item>
                <p>Dual inhibition of MCL1 and BCL2 proteins results in a durable remission in DLBCL mouse models.</p>
              </list-item>
              <list-item>
                <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S63845">S63845</ext-link> or venetoclax encapsulated in tumor-targeted nanoparticles improves the therapeutic index of the combination.</p>
              </list-item>
            </list>
          </p>
        </abstract>
        <abstract>
          <p>Cancer and normal cells use multiple antiapoptotic BCL2 proteins to prevent cell death. Therapeutic targeting of multiple BCL2 family proteins enhances tumor killing but is also associated with increased systemic toxicity. Here, we demonstrate that the dual targeting of MCL1 and BCL2 proteins using the small molecules <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S63845">S63845</ext-link> and venetoclax induces durable remissions in mice that harbor human diffuse large B-cell lymphoma (DLBCL) tumors but is accompanied by hematologic toxicity and weight loss. To mitigate these toxicities, we encapsulated <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S63845">S63845</ext-link> or venetoclax into nanoparticles that target P-selectin, which is enriched in tumor endothelial cells. In vivo and ex vivo imaging demonstrated preferential targeting of the nanoparticles to lymphoma tumors over vital organs. Mass spectrometry analyses after administration of nanoparticle drugs confirmed tumor enrichment of the drug while reducing plasma levels. Furthermore, nanoparticle encapsulation allowed 3.5- to 6.5-fold reduction in drug dose, induced sustained remissions, and minimized toxicity. Our results support the development of nanoparticles to deliver BH3 mimetic combinations in lymphoma and in general for toxic drugs in cancer therapy.</p>
        </abstract>
        <abstract abstract-type="graphical">
          <title>Visual Abstract</title>
          <p>
            <fig fig-type="featured" id="absf1" orientation="portrait" position="float">
              <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bloodBLD2020008017absf1.jpg"/>
            </fig>
          </p>
        </abstract>
        <funding-group>
          <award-group id="sp1">
            <funding-source>
              <institution-wrap>
                <institution>National Institutes of Health</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
        </funding-group>
        <counts>
          <page-count count="13"/>
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
